Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

3.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
3.3K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.2K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

4.2K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.2K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.4K
The pathophysiology of pneumonia involves the following steps:
4.4K
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

1.3K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.3K
Atypical Pneumonia01:14

Atypical Pneumonia

57
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
57

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correspondence in regard to Patil N, et al.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

Re: 'Is a 14-Day Pathway from Decision to Treat to Radiotherapy for Head and Neck Cancer Patients Feasible in the National Health Service? The Torbay Experience 5 Years On'.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

[Inactivation of Ras1 in Fission Yeast Aggravates the Oxidative Stress Response Induced by Tert Butyl Hydroperoxide (tBHP)].

Molekuliarnaia biologiia·2023
Same author

Unusual occurrence reporting system: Sharing a ten years experience from a tertiary care JCIA accredited university hospital.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2018
Same author

Presenting features, treatment patterns and outcomes of patients with breast cancer in Pakistan: Experience at a university hospital.

Indian journal of cancer·2017
Same author

Impact of a Computerized Antithrombotic Risk Assessment Tool on the Prescription of Thromboprophylaxis in Atrial Fibrillation: Hospital Setting.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2016

Related Experiment Video

Updated: Apr 12, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.3K

Everolimus induced Pneumonitis.

Q Badar1, N Masood2, A N Abbasi1

  • 1Dept of Radiation Oncology, Aga Khan University and Hospital, Karachi, Pakistan.

The Gulf Journal of Oncology
|May 25, 2015
PubMed
Summary

Everolimus, an mTOR inhibitor, can cause rare pneumonitis in patients with metastatic renal cell carcinoma. Early recognition and drug discontinuation are key for patient safety and recovery.

Area of Science:

  • Oncology
  • Pharmacology
  • Pulmonology

Background:

  • Everolimus (RAD 001) is an oral mTOR inhibitor used in organ transplantation and advanced renal cell carcinoma (RCC).
  • Noninfectious pneumonitis is a rare adverse reaction associated with mTOR inhibitors like everolimus.
  • Prompt identification and management of this toxicity are crucial for patient safety.

Purpose of the Study:

  • To report a case of everolimus-induced pneumonitis in a patient with metastatic renal cell carcinoma (mRCC).
  • To highlight the importance of recognizing and managing this rare adverse event.

Main Methods:

  • Case report of a 72-year-old male patient with mRCC.
  • Observation of adverse events following 4 months of everolimus treatment.

More Related Videos

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.4K
Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation
10:01

Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation

Published on: July 10, 2012

21.2K

Related Experiment Videos

Last Updated: Apr 12, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

2.3K
Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.4K
Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation
10:01

Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation

Published on: July 10, 2012

21.2K

Main Results:

  • The patient developed pneumonitis after 4 months of everolimus therapy.
  • Everolimus was discontinued, and the patient received appropriate treatment.
  • The patient was discharged after 10 days of hospitalization, indicating successful management.

Conclusions:

  • Everolimus-induced pneumonitis is a rare but significant toxicity.
  • Vigilance and prompt intervention are essential for managing this adverse reaction in mRCC patients.
  • Effective management can lead to patient recovery.